Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons.
about
Mouse models of Parkinson's disease associated with mitochondrial dysfunctionMitochondrial dysfunction and oxidative stress in Parkinson's diseaseProgressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in miceComplex I deficiency due to selective loss of Ndufs4 in the mouse heart results in severe hypertrophic cardiomyopathyDysregulation of autophagy and mitochondrial function in Parkinson's diseaseImpaired complex IV activity in response to loss of LRPPRC function can be compensated by mitochondrial hyperfusion.Exercise does not protect against MPTP-induced neurotoxicity in BDNF haploinsufficient mice.The respiratory chain supercomplex organization is independent of COX7a2l isoforms.Mitochondrial Diseases Part I: mouse models of OXPHOS deficiencies caused by defects in respiratory complex subunits or assembly factors.Characterization of Fast-Scan Cyclic Voltammetric Electrodes Using Paraffin as an Effective Sealant with In Vitro and In Vivo Applications.Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases.Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivoFatal breathing dysfunction in a mouse model of Leigh syndromeUnderstanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease.Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure.Alterations in mitochondrial DNA copy number and the activities of electron transport chain complexes and pyruvate dehydrogenase in the frontal cortex from subjects with autism.Glial cell line-derived neurotrophic factor partially ameliorates motor symptoms without slowing neurodegeneration in mice with respiratory chain-deficient dopamine neurons.The impact of mitochondrial DNA and nuclear genes related to mitochondrial functioning on the risk of Parkinson's disease.Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson's disease.MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian.Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.Cellular and animal models for mitochondrial complex I deficiency: a focus on the NDUFS4 subunit.The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease.Assessing the Mitochondrial Membrane Potential in Cells and In Vivo using Targeted Click Chemistry and Mass Spectrometry.MPTP's pathway of toxicity indicates central role of transcription factor SP1.Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.Mitochondria and α-Synuclein: Friends or Foes in the Pathogenesis of Parkinson's Disease?Clarifying the supercomplex: the higher-order organization of the mitochondrial electron transport chain.AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway.Mitofusin 2 is necessary for striatal axonal projections of midbrain dopamine neurons.Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease.
P2860
Q26829851-CEF87F88-3AF6-4B2E-9CEC-154B60FFDD3AQ27014051-B67C522D-2D32-4A40-B8C7-F86662DED9CAQ27308060-5585436E-9B80-4D0C-98C2-789D88EAA0E0Q27342864-5B27DE3B-FC50-4BA8-8374-132AE7589E27Q28071890-EC7583CD-A8C5-4D25-9D30-4E19B570FD37Q30542646-CE75176B-FA57-45BF-99C7-14D853B5A1AAQ34389461-03788950-432D-4D6B-B97D-33A701FBB905Q34664166-BF4C9601-B003-4BD2-96DA-993EA0EFE811Q35190973-839D1CF3-FC71-46E0-9381-C125642BFF63Q35822540-219FFE2F-0CDC-4745-84CE-420A8B5E935DQ35892854-C53F3C85-4C2C-4613-A3FE-7A4DD4DCE795Q35912064-561279D8-35FB-4BD0-82C3-60AE3117558DQ36070987-FC2CDCE4-4F7C-4E52-9E58-5CABC5684102Q36372732-218D235F-6A76-41FE-BEF0-CDB9280BD1C0Q37189263-60CBD000-335F-4A14-BEB4-51B6005788D2Q37201349-72D3A530-093A-41BC-832F-4E303FCC805BQ37466357-D9D53221-E4CF-4383-8D8F-41877D927BB3Q37583410-AA258E25-10C4-433E-93D3-369153D54058Q37591146-45A11125-FBF6-4285-B484-4A0229130D4CQ37702119-B07BDCBB-A50F-4EDA-8B51-D12EDD701A7EQ37715032-0E2E4995-EC23-4B37-A28E-7C1D3406252EQ38021865-B447A95F-C201-43E1-9D44-50D5B9D65614Q38074802-FE26AA11-AC47-43CE-A21B-C2CFC03D15B3Q38078887-4149DA2D-89EC-422A-B889-BCBD2CF6CD28Q38202314-F2775D2A-0617-45B6-A8DB-8299751475DFQ38411199-FD33E4A3-E7F3-4A2E-B57C-E1E5A6095918Q40124758-6527D679-940C-452E-ACFD-79927360CBA1Q43679571-2F84F253-A3A7-49AD-8D80-37A7ACED39E2Q47239603-F3EA41ED-9B21-4429-AEC6-820A976EF30DQ47693620-985A65AB-3540-4A48-BC0D-FBDC5EA43F2AQ47935763-0852AA7D-F4C1-4015-B4AC-014667BD90ACQ48401711-973FB33C-8454-4F5C-A3D3-E4E70C8607ABQ55048859-DDF7FE29-C546-47C8-BAAF-B5A71AFE6ADD
P2860
Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Altered dopamine metabolism an ...... complex I in dopamine neurons.
@ast
Altered dopamine metabolism an ...... complex I in dopamine neurons.
@en
type
label
Altered dopamine metabolism an ...... complex I in dopamine neurons.
@ast
Altered dopamine metabolism an ...... complex I in dopamine neurons.
@en
prefLabel
Altered dopamine metabolism an ...... complex I in dopamine neurons.
@ast
Altered dopamine metabolism an ...... complex I in dopamine neurons.
@en
P2093
P2860
P356
P1476
Altered dopamine metabolism an ...... complex I in dopamine neurons.
@en
P2093
Alexander F Hoffman
Arianna Paganelli
Carl R Lupica
Daniel Edgar
Dusanka Milenkovic
Fredrik H Sterky
Lars Olson
Rolf Wibom
P2860
P304
P356
10.1093/HMG/DDR537
P577
2011-11-16T00:00:00Z